Intranasal Ketorolac Tromethamine (SPRIX) as a Short Term Pain Management of Post-Vasectomy Pain


To evaluate the efficacy, tolerability and safety of intranasal ketorolac tromethamine (SPRIX) as an option for pain management in post vasectomy patients.

Full Title of Study: “Efficacy and Safety of Intranasal Ketorolac Tromethamine (SPRIX) as a Short Term Pain Management Tool for Adult Male Patients With Post-Vasectomy Pain”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Non-Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: December 2013


  • Drug: Ketorolac Tromethamine
  • Other: Standard of Care

Arms, Groups and Cohorts

  • Other: Ketorolac tromethamine (SPRIX)
    • A SPRIX dose will be one 15.75 mg spray in each nostril for a total dose of 31.5 mg which can be repeated every 6-8 hrs as needed for post vasectomy pain with a maximum daily dose of 126 mg to be continued for up to 5 days.
  • Other: Standard of care
    • The intervention used will be standard of care

Clinical Trial Outcome Measures

Primary Measures

  • Pain Scores on the Visual Analog Scale
    • Time Frame: 5 days

Secondary Measures

  • To determine Number of Participants with Adverse Events as a Measure of Safety and Tolerability
    • Time Frame: 5 Days

Participating in This Clinical Trial

Inclusion Criteria

1. Male Subject must be between the age twenty five (25) years and sixty four (64)

2. Willing and able to provide an informed consent

3. Has made decision to undergo vasectomy

4. Subject is in good general physical condition as assessed by the Principal Investigator

Exclusion Criteria

1. Current treatment with or known allergy or sensitivity to all forms of ketorolac tromethamine , aspirin , other non steroidal anti inflammatory drugs (NSAIDs) or Ethylenediaminetetraacetic acid (EDTA)

2. Use of narcotics/opiate or medical marijuana within one (1) week prior to the baseline visit and entire study participation

3. Use of illegal drugs by self reporting

4. History of drug or alcohol abuse within five (5) years of screening visit

5. History of suicide attempt within five (5) years of screening visit

6. A diagnosis of a severe neuro-psychiatric disease

7. Subject who is currently receiving investigational drug(s) or participated in a clinical trial involving investigational drug(s) within thirty (30) day of the screening visit

8. Subject with history of any of the following coronary conditions: (chronic stable angina being currently treated with long acting nitrates, chronic stable angina require treatment with short acting nitrates with 90 days of visit 1, angina occurring during sexual intercourse in the last six months, unstable angina within six months of visit 1

9. Resting, sitting blood pressure (BP) > 160mm Hg in systolic pressure or > 100mm Hg is diastolic pressure at screening. If a patient is found to have untreated significant hypertension at screening and antihypertensive treatment is initiated, assessment for study eligibility should be deferred until BP and antihypertensive medication have been stable for at least one month. For patients with previously diagnosed hypertension, antihypertensive medications must be stable for at least one month prior to screening.

10. Known or suspected cerebrovascular bleeding, hemorrhagic diathesis or incomplete hemostasis, and those at high risk of bleeding, have history of a bleeding problem or low platelet count or coagulation disorder or are on therapy that affects homeostasis

11. Active peptic ulcer disease, recent GI bleeding or perforation, or a history of peptic ulcers or GI bleeding

12. History of asthma, urticaria or other allergic-type reaction after taking aspirin or other non steroidal inflammatory drugs (NASIDs)

13. Subject over sixty four (64) years of age

14. Subject with any clinically significant renal function or liver abnormality

15. Subject who has history of swelling of face, mouth, tongue, lips, gums, neck, or throat (angioedema) or with cardiac decompensation or similar conditions

16. Major surgery scheduled within 3 weeks or screening and for entire participation of study

17. Current exfoliative dermatitis, Stevens-Johnson syndrome or toxic epidermal necrolysis

18. Any condition in the opinion of the investigator that makes the subject unsuitable for study

Gender Eligibility: Male

Minimum Age: 25 Years

Maximum Age: 64 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Citrus Valley Medical Research, Inc.
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Edward L Davis, M.D., Principal Investigator, Citrus Valley Medical Research, Inc.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.